| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
1.09(B) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.88 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.3 |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 16.7 |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
17,604 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$160,420 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
3 |
3 |
| Total Shares Sold |
123,875 |
414,717 |
427,025 |
1,110,810 |
| Total Sell Value |
$798,994 |
$5,191,225 |
$5,313,647 |
$13,073,359 |
| Total People Sold |
4 |
6 |
6 |
9 |
| Total Sell Transactions |
4 |
10 |
13 |
48 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mccourt Thomas A |
Chief Commercial Officer |
• – – |
2019-02-21 |
4 |
AS |
$14.32 |
$587 |
D/D |
(41) |
83,309 |
|
- |
|
| Gilbert Halley E |
Chief Legal Officer |
• – – |
2019-02-20 |
4 |
AS |
$14.31 |
$145,347 |
D/D |
(10,157) |
225,215 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2019-02-20 |
4 |
AS |
$14.31 |
$23,340 |
D/D |
(1,631) |
803,493 |
|
- |
|
| Consylman Gina |
Chief Financial Officer |
• – – |
2019-02-20 |
4 |
AS |
$14.31 |
$80,580 |
D/D |
(5,631) |
163,230 |
|
- |
|
| Mccourt Thomas A |
Chief Commercial Officer |
• – – |
2019-02-20 |
4 |
AS |
$14.31 |
$68,688 |
D/D |
(4,800) |
83,350 |
|
- |
|
| Gilbert Halley E |
Chief Legal Officer |
• – – |
2019-01-30 |
4 |
OE |
$4.89 |
$99,996 |
D/D |
20,449 |
235,372 |
|
- |
|
| Huyett William |
Chief Operating Officer |
• – – |
2019-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
43,125 |
111,375 |
|
- |
|
| Gilbert Halley E |
Chief Legal Officer |
• – – |
2019-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
72,500 |
214,923 |
|
- |
|
| Consylman Gina |
Chief Financial Officer |
• – – |
2019-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
72,500 |
168,861 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2019-01-25 |
4 |
OE |
$4.89 |
$244,500 |
D/D |
50,000 |
4,717,366 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2019-01-25 |
4 |
AS |
$12.23 |
$361,409 |
D/D |
(29,551) |
4,696,917 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2019-01-24 |
4 |
AS |
$12.70 |
$381,000 |
D/D |
(30,000) |
4,696,917 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2019-01-24 |
4 |
OE |
$4.89 |
$146,700 |
D/D |
30,000 |
4,726,917 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2019-01-23 |
4 |
AS |
$12.66 |
$379,800 |
D/D |
(30,000) |
4,696,917 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2019-01-23 |
4 |
OE |
$4.89 |
$146,700 |
D/D |
30,000 |
4,726,917 |
|
- |
|
| Mallon Mark |
Executive Senior Advisor |
• – – |
2019-01-09 |
4 |
A |
$0.00 |
$0 |
D/D |
93,036 |
93,036 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
4,696,917 |
4,696,917 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2018-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,696,917) |
0 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
775,000 |
805,124 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(775,000) |
0 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
40,000 |
69,117 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2018-12-31 |
4 |
D |
$0.00 |
$0 |
I/I |
(40,000) |
0 |
|
- |
|
| Fanucci Marsha |
Director |
– • – |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
44,863 |
136,719 |
|
- |
|
| Fanucci Marsha |
Director |
– • – |
2018-12-31 |
4 |
D |
$0.00 |
$0 |
D/D |
(44,863) |
0 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
212 |
77,503 |
|
- |
|
584 Records found
|
|
Page 13 of 24 |
|
|
0.24 (3.96%) 
